NOD2 stimulation by Staphylococcus aureus-derived peptidoglycan is boosted by toll-like receptor 2 costimulation with lipoproteins in dendritic cells

Infection and Immunity

Volumn 82, Issue 11, 2014, Pages 4681-4688

  Schäffler, Holger ^a   Demircioglu, Dogan Doruk ^b   Kühner, Daniel ^b   Menz, Sarah ^b,c   Bender, Annika ^b,c   Autenrieth, Ingo B ^b,c   Bodammer, Peggy ^a   Lamprecht, Georg ^a   Götz, Friedrich ^b   Frick, Julia Stefanie ^b,c  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOKINE; INTERLEUKIN 12P40; INTERLEUKIN 6; LIPOPROTEIN; PEPTIDOGLYCAN; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; CARD15 PROTEIN, MOUSE; TLR2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BONE MARROW DERIVED DENDRITIC CELL; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INNATE IMMUNITY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; ANIMAL; BONE MARROW CELL; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; BONE MARROW CELLS; CELLS, CULTURED; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; LIPOPROTEINS; MICE; MICE, KNOCKOUT; NOD2 SIGNALING ADAPTOR PROTEIN; PEPTIDOGLYCAN; STAPHYLOCOCCUS AUREUS; TOLL-LIKE RECEPTOR 2;

EID: 84907960394     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02043-14     Document Type: Article

References (43)

1. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG. 2001. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357:1925-1928. http://dx.doi.org/10.1016/S0140-6736(00)05063-7.
2. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. 2001. Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature 411:599-603. http://dx.doi.org/10.1038/35079107.
3. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606. http://dx.doi.org/10.1038/35079114.
4. Strober W, Murray PJ, Kitani A, Watanabe T. 2006. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat. Rev. Immunol. 6:9-20. http://dx.doi.org/10.1038/nri1747.
5. Ng SC, Kamm MA, Stagg AJ, Knight SC. 2010. Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation. Inflamm. Bowel Dis. 16:1787-1807. http://dx.doi.org/10.1002/ibd.21247.
6. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, Vyas JM, Boes M, Ploegh HL, Fox JG, Littman DR, Reinecker HC. 2005. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307:254-258. http://dx.doi.org/10.1126/science.1102901.
7. Coombes JL, Powrie F. 2008. Dendritic cells in intestinal immune regulation. Nat. Rev. Immunol. 8:435-446. http://dx.doi.org/10.1038/nri2335.
8. Strober W. 2009. The multifaceted influence of the mucosal microflora on mucosal dendritic cell responses. Immunity 31:377-388. http://dx.doi.org/10.1016/j.immuni.2009.09.001.
9. Iwasaki A, Medzhitov R. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-995. http://dx.doi.org/10.1038/ni1112.
10. Baumgart DC, Sandborn WJ. 2012. Crohn's disease. Lancet 380:1590-1605. http://dx.doi.org/10.1016/S0140-6736(12)60026-9.
11. Niess JH. 2008. Role of mucosal dendritic cells in inflammatory bowel disease. World J. Gastroenterol. 14:5138-5148. http://dx.doi.org/10.3748/wjg.14.5138.
12. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ. 2005. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129:50-65. http://dx.doi.org/10.1053/j.gastro.2005.05.013.
13. Iliev ID, Spadoni I, Mileti E, Matteoli G, Sonzogni A, Sampietro GM, Foschi D, Caprioli F, Viale G, Rescigno M. 2009. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut 58:1481-1489. http://dx.doi.org/10.1136/gut.2008.175166.
14. Volz T, Nega M, Buschmann J, Kaesler S, Guenova E, Peschel A, Rocken M, Götz F, Biedermann T. 2010. Natural Staphylococcus aureusderived peptidoglycan fragments activate NOD2 and act as potent costimulators of the innate immune system exclusively in the presence of TLR signals. FASEB J. 24:4089-4102. http://dx.doi.org/10.1096/fj.09-151001.
15. Hashimoto M, Tawaratsumida K, Kariya H, Kiyohara A, Suda Y, Krikae F, Kirikae T, Götz F. 2006. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J. Immunol. 177:3162-3169. http://dx.doi.org/10.4049/jimmunol.177.5.3162.
16. Iyer JK, Coggeshall KM. 2011. Cutting edge: primary innate immune cells respond efficiently to polymeric peptidoglycan, but not to peptidoglycan monomers. J. Immunol. 186:3841-3845. http://dx.doi.org/10.4049/jimmunol.1004058.
17. Bera A, Herbert S, Jakob A, Vollmer W, Götz F. 2005. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan Oacetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol. Microbiol. 55:778-787. http://dx.doi.org/10.1111/j.1365-2958.2004.04446.x.
18. Bera A, Biswas R, Herbert S, Götz F. 2006. The presence of peptidoglycan O-acetyltransferase in various staphylococcal species correlates with lysozyme resistance and pathogenicity. Infect. Immun. 74:4598-4604. http://dx.doi.org/10.1128/IAI.00301-06.
19. Herbert S, Bera A, Nerz C, Kraus D, Peschel A, Goerke C, Meehl M, Cheung A, Götz F. 2007. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog. 3:e102. http://dx.doi.org/10.1371/journal.ppat.0030102.
20. Shimada T, Park BG, Wolf AJ, Brikos C, Goodridge HS, Becker CA, Reyes CN, Miao EA, Aderem A, Götz F, Liu GY, Underhill DM. 2010. Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1beta secretion. Cell Host Microbe 7:38-49. http://dx.doi.org/10.1016/j.chom.2009.12.008.
21. Netea MG, Kullberg BJ, de Jong DJ, Franke B, Sprong T, Naber TH, Drenth JP, Van der Meer JW. 2004. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur. J. Immunol. 34:2052-2059. http://dx.doi.org/10.1002/eji.200425229.
22. Watanabe T, Kitani A, Murray PJ, Strober W. 2004. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5:800-808. http://dx.doi.org/10.1038/ni1092.
23. Dahiya Y, Pandey RK, Sodhi A. 2011. Nod2 downregulates TLR2/1 mediated IL1beta gene expression in mouse peritoneal macrophages. PLoS One 6:e27828. http://dx.doi.org/10.1371/journal.pone.0027828.
24. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, Flavell RA. 2005. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307:731-734. http://dx.doi.org/10.1126/science.1104911.
25. Travassos LH, Girardin SE, Philpott DJ, Blanot D, Nahori MA, Werts C, Boneca IG. 2004. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep. 5:1000-1006. http://dx.doi.org/10.1038/sj.embor.7400248.
26. Müller-Anstett MA, Muller P, Albrecht T, Nega M, Wagener J, Gao Q, Kaesler S, Schaller M, Biedermann T, Götz F. 2010. Staphylococcal peptidoglycan co-localizes with Nod2 and TLR2 and activates innate immune response via both receptors in primary murine keratinocytes. PLoS One 5:e13153. http://dx.doi.org/10.1371/journal.pone.0013153.
27. Hashimoto M, Tawaratsumida K, Kariya H, Aoyama K, Tamura T, Suda Y. 2006. Lipoprotein is a predominant Toll-like receptor 2 ligand in Staphylococcus aureus cell wall components. Int. Immunol. 18:355-362. http://dx.doi.org/10.1093/intimm/dxh374.
28. Schmaler M, Jann NJ, Ferracin F, Landolt LZ, Biswas L, Götz F, Landmann R. 2009. Lipoproteins in Staphylococcus aureus mediate inflammation by TLR2 and iron-dependent growth in vivo. J. Immunol. 182:7110-7118. http://dx.doi.org/10.4049/jimmunol.0804292.
29. Zahringer U, Lindner B, Inamura S, Heine H, Alexander C. 2008. TLR2-promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213:205-224. http://dx.doi.org/10.1016/j.imbio.2008.02.005.
30. Stoll H, Dengjel J, Nerz C, Götz F. 2005. Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation. Infect. Immun. 73:2411-2423. http://dx.doi.org/10.1128/IAI.73.4.2411-2423.2005.
31. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223:77-92. http://dx.doi.org/10.1016/S0022-1759(98)00204-X.
32. de Jonge BL, Chang YS, Gage D, Tomasz A. 1992. Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain. The role of penicillin binding protein 2A. J. Biol. Chem. 267:11248-11254.
33. Glauner B. 1988. Separation and quantification of muropeptides with high-performance liquid chromatography. Anal. Biochem. 172:451-464. http://dx.doi.org/10.1016/0003-2697(88)90468-X.
34. Mizgerd JP, Spieker MR, Doerschuk CM. 2001. Early response cytokines and innate immunity: essential roles for TNF receptor 1 and type I IL-1 receptor during Escherichia coli pneumonia in mice. J. Immunol. 166:4042-4048. http://dx.doi.org/10.4049/jimmunol.166.6.4042.
35. Strober W, Kitani A, Fuss I, Asano N, Watanabe T. 2008. The molecular basis of NOD2 susceptibility mutations in Crohn's disease. Mucosal Immunol. 1(Suppl 1):S5-S9. http://dx.doi.org/10.1038/mi.2008.42.
36. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. 2003. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278:8869-8872. http://dx.doi.org/10.1074/jbc.C200651200.
37. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nunez G. 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278:5509-5512. http://dx.doi.org/10.1074/jbc.C200673200.
38. Natsuka M, Uehara A, Yang S, Echigo S, Takada H. 2008. A polymertype water-soluble peptidoglycan exhibited both Toll-like receptor 2- and NOD2-agonistic activities, resulting in synergistic activation of human monocytic cells. Innate Immun. 14:298-308. http://dx.doi.org/10.1177/1753425908096518.
39. Cella M, Sallusto F, Lanzavecchia A. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:10-16. http://dx.doi.org/10.1016/S0952-7915(97)80153-7.
40. Peluso I, Pallone F, Monteleone G. 2006. Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J. Gastroenterol. 12:5606-5610.
41. Magalhaes JG, Fritz JH, Le Bourhis L, Sellge G, Travassos LH, Selvanantham T, Girardin SE, Gommerman JL, Philpott DJ. 2008. Nod2-dependent Th2 polarization of antigen-specific immunity. J. Immunol. 181:7925-7935. http://dx.doi.org/10.4049/jimmunol.181.11.7925.
42. Watanabe T, Asano N, Murray PJ, Ozato K, Tailor P, Fuss IJ, Kitani A, Strober W. 2008. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J. Clin. Invest. 118:545-559. http://dx.doi.org/10.1172/JCI33145.
43. Macho Fernandez E, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, Grangette C. 2011. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 60:1050-1059. http://dx.doi.org/10.1136/gut.2010.232918.